STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
prasugrel
POPular AGE Trial Summary: Antiplatelet agent in NSTEMI
2020 POPULAR AGE TRIAL Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome multicenter, randomized controlled trial Objective: To evaluate the effectiveness of clopidogrel compared with ticagrelor or prasugrel among patients ≥70 … Read More